Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10756089rdf:typepubmed:Citationlld:pubmed
pubmed-article:10756089lifeskim:mentionsumls-concept:C0004358lld:lifeskim
pubmed-article:10756089lifeskim:mentionsumls-concept:C0026272lld:lifeskim
pubmed-article:10756089lifeskim:mentionsumls-concept:C0206138lld:lifeskim
pubmed-article:10756089lifeskim:mentionsumls-concept:C0022702lld:lifeskim
pubmed-article:10756089pubmed:issue3lld:pubmed
pubmed-article:10756089pubmed:dateCreated2000-6-26lld:pubmed
pubmed-article:10756089pubmed:abstractTextUsing a highly sensitive Radioimmunoassay (RIA), the kinetics of synthesis of anti-fibrillin (Fbn-1) autoantibodies were studied in 17 patients with mixed connective tissue disease (MCTD) and two with CREST syndrome calcinosis, Raynaud's oesophageal dismotility, sclerodectyly and teleangiectasis who were found to be positive for this autoimmune response. IgG autoantibodies specific for recombinant Fbn-1 (rFbn-1) (aa 369-425) were found in all patients excepting one with MCTD, multiple sclerosis, and dermatomyositis. IgM were found in fewer cases. Several kinetics patterns of anti-Fbn-1 autoantibodies were observed: a) long lasting persistence of IgG and IgM autoantibodies up to 14 years; b) fluctuation of antibodies during various periods up to 16 years; c) disappearance of antibody response after several years, and d) patients producing IgG but not IgM autoantibodies. No differences in the synthesis of autoantibodies were observed between MCTD patients with a stable disease, and those developing during the course features of systemic sclerosis (SSc), Sjogren's syndrome, or rheumatoid-like arthritis. In one patient displaying a lupus-like syndrome for 3 years, the appearance of anti-Fbn-1 autoantibodies coincided with the occurrence of MCTD and scleroderma. While the detection of anti-Fbn-1 autoantibodies may be clinically useful in differential diagnosis or eventual prognosis of patients with connective tissue diseases, their role in the pathogenesis of scleroderma syndromes requires further investigation.lld:pubmed
pubmed-article:10756089pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10756089pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10756089pubmed:languageenglld:pubmed
pubmed-article:10756089pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10756089pubmed:citationSubsetIMlld:pubmed
pubmed-article:10756089pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10756089pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10756089pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10756089pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10756089pubmed:statusMEDLINElld:pubmed
pubmed-article:10756089pubmed:monthMaylld:pubmed
pubmed-article:10756089pubmed:issn0896-8411lld:pubmed
pubmed-article:10756089pubmed:authorpubmed-author:SteinerGGlld:pubmed
pubmed-article:10756089pubmed:authorpubmed-author:BonaCClld:pubmed
pubmed-article:10756089pubmed:authorpubmed-author:KlareskogLLlld:pubmed
pubmed-article:10756089pubmed:authorpubmed-author:AntohiSSlld:pubmed
pubmed-article:10756089pubmed:authorpubmed-author:LundbergIIlld:pubmed
pubmed-article:10756089pubmed:authorpubmed-author:BrumeanuT DTDlld:pubmed
pubmed-article:10756089pubmed:authorpubmed-author:ArnettFFlld:pubmed
pubmed-article:10756089pubmed:authorpubmed-author:TakeukiKKlld:pubmed
pubmed-article:10756089pubmed:copyrightInfoCopyright 2000 Academic Press.lld:pubmed
pubmed-article:10756089pubmed:issnTypePrintlld:pubmed
pubmed-article:10756089pubmed:volume14lld:pubmed
pubmed-article:10756089pubmed:ownerNLMlld:pubmed
pubmed-article:10756089pubmed:authorsCompleteYlld:pubmed
pubmed-article:10756089pubmed:pagination267-74lld:pubmed
pubmed-article:10756089pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:10756089pubmed:meshHeadingpubmed-meshheading:10756089...lld:pubmed
pubmed-article:10756089pubmed:meshHeadingpubmed-meshheading:10756089...lld:pubmed
pubmed-article:10756089pubmed:meshHeadingpubmed-meshheading:10756089...lld:pubmed
pubmed-article:10756089pubmed:meshHeadingpubmed-meshheading:10756089...lld:pubmed
pubmed-article:10756089pubmed:meshHeadingpubmed-meshheading:10756089...lld:pubmed
pubmed-article:10756089pubmed:meshHeadingpubmed-meshheading:10756089...lld:pubmed
pubmed-article:10756089pubmed:meshHeadingpubmed-meshheading:10756089...lld:pubmed
pubmed-article:10756089pubmed:year2000lld:pubmed
pubmed-article:10756089pubmed:articleTitleKinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome.lld:pubmed
pubmed-article:10756089pubmed:affiliationDepartment of Rheumatology, Karolinska Hospital, Stockholm, Sweden.lld:pubmed
pubmed-article:10756089pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10756089pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10756089pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed